Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials

Published:2024-05-13 Issue:1 Volume:56 Page:
ISSN:0785-3890
Container-title:Annals of Medicine
language:en
Short-container-title:Annals of Medicine

Author:

Yang Xiu Hong¹²,Zhang Bao Long³,Cheng Yun¹,Fu Shun Kun¹,Jin Hui Min¹⁴

Affiliation:

1. Department of Nephrology, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center, Shanghai, China

2. Department of Nephrology, Huadong Hospital, Fudan University, Shanghai, China

3. The Institutes of Biomedical Sciences (IBS), Fudan University, Shanghai, China

4. Department of Nephrology, The People’s Hospital of Wenshan Prefecture, Yunnan Province, China

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/07853890.2024.2332956

Reference37 articles.

1. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

2. Febuxostat Use and Risks of Cardiovascular Disease Events, Cardiac Death, and All-cause Mortality: Metaanalysis of Randomized Controlled Trials

3. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis

4. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis

5. Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP